AzTrials
AzTrials

SchizophreniaPhase 3NCT00257192

Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

A Phase 3 study testing Ziprasidone oral capsules in people with Schizophrenia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 92 sites in 9 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia Read more about this study

Who is it for?
Ages 13 to 17 years
Conditions the study is for
Schizophrenia
What is being tested?
Ziprasidone oral capsules
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
284 participants
Where
92 sitesin 9 countries
Study dates
Apr 2006to Mar 2009
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for schizophrenia: Current symptoms were to be present for at least 7 days before screening.
  • At the Screening and Baseline visits, subjects must have had a Brief Psychiatric Rating Scale - Anchored score ≥35 and a score of ≥4 on at least 1 of the following items: unusual thought content (i.e., delusions), hallucinations, suspiciousness, or conceptual disorganization.
  • Age 13 - 17 years

Who cannot join

  • Imminent risk of suicide or homicide, as judged by the site investigator
  • Any history of serious or unstable medical illness, including risk for QT prolongation

Trial locations and contacts

92 sites in 9 countries.

92 sites in 9 countries

United States46 sites
  • Pfizer Investigational Site

    Altamonte Springs, Florida, 32701

  • Pfizer Investigational Site

    Arlington, Texas, 76011

  • Pfizer Investigational Site

    Aurora, Colorado, 80045

  • Pfizer Investigational Site

    Birmingham, Alabama, 35205

  • Pfizer Investigational Site

    Birmingham, Alabama, 35294-4400

  • Pfizer Investigational Site

    Birmingham, Alabama, 35294

  • Pfizer Investigational Site

    Bothell, Washington, 98011

  • Pfizer Investigational Site

    Bridgeton, Missouri, 63044-2588

  • Pfizer Investigational Site

    Buffalo, New York, 14209

  • Pfizer Investigational Site

    Buffalo, New York, 14215

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45219

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45224

  • Pfizer Investigational Site

    Cincinnati, Ohio, 45229

  • Pfizer Investigational Site

    Cleveland, Ohio, 44106

  • Pfizer Investigational Site

    Clinton Township, Michigan, 48038

  • Pfizer Investigational Site

    Des Plaines, Illinois, 60016

  • Pfizer Investigational Site

    DeSoto, Texas, 75115

  • Pfizer Investigational Site

    Fort Lauderdale, Florida, 33301

  • Pfizer Investigational Site

    Honolulu, Hawaii, 96813

  • Pfizer Investigational Site

    Lincoln, Nebraska, 68510

  • Pfizer Investigational Site

    Meridian, Mississippi, 39301

  • Pfizer Investigational Site

    Milwaukee, Wisconsin, 53226

  • Pfizer Investigational Site

    North Miami, Florida, 33161

  • Pfizer Investigational Site

    Oakbrook Terrace, Illinois, 60181

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73101

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73107

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma, 73116

  • Pfizer Investigational Site

    Omaha, Nebraska, 68131

  • Pfizer Investigational Site

    Orange City, Florida, 32763

  • Pfizer Investigational Site

    Pikesville, Maryland, 21208

  • Pfizer Investigational Site

    Plano, Texas, 75093

  • Pfizer Investigational Site

    Rochester, New York, 14618

  • Pfizer Investigational Site

    San Diego, California, 92123

  • Pfizer Investigational Site

    Schaumburg, Illinois, 60194

  • Pfizer Investigational Site

    Smyrna, Georgia, 30080

  • Pfizer Investigational Site

    Spokane, Washington, 99204

  • Pfizer Investigational Site

    Spokane, Washington, 99216

  • Pfizer Investigational Site

    St Louis, Missouri, 63141

  • Pfizer Investigational Site

    Stanford, California, 94305

  • Pfizer Investigational Site

    Tampa, Florida, 33613

  • Pfizer Investigational Site

    Tavares, Florida, 32778

  • Pfizer Investigational Site

    Towson, Maryland, 21204

  • Pfizer Investigational Site

    Towson, Maryland, 21286

  • Pfizer Investigational Site

    Tucker, Georgia, 30084

  • Pfizer Investigational Site

    Washington D.C., District of Columbia, 20010

  • Pfizer Investigational Site

    West Allis, Wisconsin, 53227

Other trials in United States

Russia14 sites
  • Pfizer Investigational Site

    Kazan', 420012

  • Pfizer Investigational Site

    Khotkovo, Moscow Region, 142601

  • Pfizer Investigational Site

    Lipetsk Region, 399313

  • Pfizer Investigational Site

    Moscow, 107076

  • Pfizer Investigational Site

    Moscow, 115522

  • Pfizer Investigational Site

    Moscow, 117152

  • Pfizer Investigational Site

    Moscow, 127473

  • Pfizer Investigational Site

    Moscow, 143300

  • Pfizer Investigational Site

    Nizhny Novgorod, 603155

  • Pfizer Investigational Site

    Saint Petersburg, 192019

  • Pfizer Investigational Site

    Saratov, 410012

  • Pfizer Investigational Site

    Saratov, 410060

  • Pfizer Investigational Site

    Tver', 170005

  • Pfizer Investigational Site

    Yaroslavl, 150003

Other trials in Russia

Ukraine11 sites
  • Pfizer Investigational Site

    Dnipropetrovsk, 49005

  • Pfizer Investigational Site

    Dnipropetrovsk, 49115

  • Pfizer Investigational Site

    Donetsk, 83037

  • Pfizer Investigational Site

    Kharkiv, 61068

  • Pfizer Investigational Site

    Kyiv, 04655

  • Pfizer Investigational Site

    Luhansk, 91045

  • Pfizer Investigational Site

    Lviv, 79021

  • Pfizer Investigational Site

    Odesa, 65006

  • Pfizer Investigational Site

    Poltava, 36006

  • Pfizer Investigational Site

    Simferopol, Autonomous Republic of Crimea, 95006

  • Pfizer Investigational Site

    Vinnytsia, 21005

Other trials in Ukraine

India10 sites
  • Pfizer Investigational Site

    Ahmedabad, Guj, 380015

  • Pfizer Investigational Site

    Chennai, Tamil Nadu, 600 003

  • Pfizer Investigational Site

    Chhatrapati Sambhajinagar, Maharashtra, 431 005

  • Pfizer Investigational Site

    Ludhiana, Punjab, 141001

  • Pfizer Investigational Site

    Mangalore, Karnataka, 575001

  • Pfizer Investigational Site

    Mumbai, Maharashtra, 400 058

  • Pfizer Investigational Site

    Pune, Maharashtra, 411 001

  • Pfizer Investigational Site

    Pune, Maharashtra, 411 046

  • Pfizer Investigational Site

    Vijaywada, Andhra Pradesh, 520 002

  • Pfizer Investigational Site

    Visakhapatnam, Andra Pradesh/India, 530 017

Other trials in India

Malaysia4 sites
  • Pfizer Investigational Site

    Kuala Lumpur, 50586

  • Pfizer Investigational Site

    Kuala Lumpur, 50603

  • Pfizer Investigational Site

    Kuala Lumpur, 55100

  • Pfizer Investigational Site

    Kubang Kerian, Kelantan, 16150

Other trials in Malaysia

Colombia2 sites
  • Pfizer Investigational Site

    Bogota, Cundinamarca

  • Pfizer Investigational Site

    Medellín, Antioquia

Other trials in Colombia

Peru2 sites
  • Pfizer Investigational Site

    Lima, L13

  • Pfizer Investigational Site

    Lima, L41

Other trials in Peru

Singapore2 sites
  • Pfizer Investigational Site

    Singapore, 229899

  • Pfizer Investigational Site

    Singapore, 539747

Other trials in Singapore

Costa Rica1 site
  • Pfizer Investigational Site

    San José

Other trials in Costa Rica

About this study

Official title: Six Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Adolescent Subjects With Schizophrenia

The purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of adolescents (ages 13-17) with schizophrenia

Read the detailed description

Termination Reason: On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.

Conditions
Schizophrenia
Being tested
placebo, Ziprasidone oral capsules
Keywords
Adolescent Subjects With Schizophrenia
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • placeboDrug

    Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.

  • Ziprasidone oral capsulesDrug

    Also called Geodon, Zeldox

    Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.

Study groups in NCT00257192
Study groupRoleWhat they receive
2.0Placebo comparatorNot described
Receives: Drug: placebo
1.0Active comparatorNot described
Receives: Drug: Ziprasidone oral capsules

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score at Week 6

    BPRS-A: 18-item clinician rated scale to assess somatic concern, anxiety, emotional withdrawal, disorganization, hallucinatory behavior, guilt feelings, suspiciousness, disorientation, tension, mannerisms, posturing, grandiosity, depressive mood, hostility, motor retardation, uncooperativeness, unusual thought content, blunted affect, and excitement. Ratings anchored to improve consistency for a single rater over time or between raters. Items rated on 7-point scale 0 (not present) to 6 (extremely severe). Total score=sum of items (range 0 to 108); higher scores indicate increased pathology.

    Measured: Baseline, Week 6

Secondary outcomes (18)
  1. Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 6

    CGI-S: single-item clinician rated scale to rate the severity of a subject's illness over time. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects); higher score indicates more affected.

    Measured: Baseline, Week 6

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 6

    PANSS: 30-item clinician-rated scale to measure severity of psychopathology (16 items); positive scale (7 items); negative scale (7 items); summarized as positive score, negative score, and total score. Items scored on anchored Likert scale rated 1 (absent symptoms) to 7 (extreme); scores above 1 indicate clinical symptom is present; scores from 2 to 7 indicate increased severity. Total score range 30 to 210: higher score indicates greater severity.

    Measured: Baseline, Week 6

  3. Change From Baseline in PANSS: Positive and Negative Subscales at Week 6

    PANSS: 30-item clinician-rated scale to measure severity of psychopathology (16 items); positive scale (7 items); negative scale (7 items); summarized as positive score, negative score, and total score. Items scored on anchored Likert scale rated 1 (absent symptoms) to 7 (extreme); scores above 1 indicate clinical symptom is present; scores from 2 to 7 indicate increased severity. Total score range 30 to 210: higher score indicates greater severity.

    Measured: Baseline, Week 6

  4. Clinical Global Impression of Improvement (CGI-I) Score at Week 6

    CGI-I: single-item clinician rated scale used to assess the subject's improvement or worsening from baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse); higher score indicates more affected.

    Measured: Baseline, Week 6

  5. Change From Baseline in Children's Global Assessment Scale (CGAS)

    CGAS: clinician-rated global assessment item for children based on symptoms and social functioning in home, school, and community settings. Scores on this single item range from 1 to 100 (higher levels indicate greater health) with descriptive anchors for every 10-point interval. Scores above 70 on this scale are considered within the "normal" range; lower score indicates need for increased supervision.

    Measured: Baseline, Week 2, Week 4, Week 6, Early termination (ET)

  6. Change From Baseline in Child Health Questionnaire (CHQ)

    CHQ: 50-item, 15 subscale parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents; rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Global indicators for Physical Health and Psychosocial Health are weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

    Measured: Baseline, Week 6, ET

  7. Change From Baseline in Children's Problem Behavior and Aggression Questionnaire (CPBAQ) Total Score

    CPBAQ: 19-item parent or legal guardian completed questionnaire to rate the child's verbal (such as yelling or cursing) and physical aggression (such a fighting with peers or being cruel to an animal) during the past week. Behavior was rated on a 4-point scale; range 0 (behavior did not occur or was not a problem) to 3 (behavior occurred a lot or was severe problem). Total score range 0 to 57; higher scores indicate a greater frequency and severity of aggression.

    Measured: Baseline, Week 1 through Week 6

  8. Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Total Score

    CDRS-R: clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment.

    Measured: Baseline, Week 1 through Week 6

  9. Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Suicide Ideation Item 13

    CDRS-R: clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Suicide Ideation (Item 13) detects changes in suicidality over time. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment).

    Measured: Baseline, Week 1 through Week 6

  10. Change From Baseline in Child Depression Rating Scale - Revised (CDRS-R): Impaired Schoolwork Item 1

    Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses resolved by using most impaired rating given by valid informant. Impaired Schoolwork (Item 1) assesses school function for the subgroup of subjects reported to be in school. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment).

    Measured: Baseline, Week 2, Week 6

  11. Change From Baseline in CNS Vital Signs Cognitive Test Battery (Includes Sedation Item): Subscales

    A computerized subject-administered test battery with subtests for verbal and visual memory, processing speed, nonverbal reasoning, executive functioning, working memory, and sustained attention. A computerized 7-point sedation item (0 [not sleepy] to 10 [very sleepy]) was completed prior to test battery. The Neurocognitive index score was derived from subtest scores per an algorithm. The index score and subtest scores assessed the subject's changes in cognition. Scores were rated as above average (score >109), average (90 to 109), below average (80 to 89), or well below average (70 to 79).

    Measured: Baseline, Week 6, ET

  12. Change From Baseline in CNS Vital Signs Cognitive Test Battery: Neurocognitive Index

    A computerized subject-administered test battery with subtests for verbal and visual memory, processing speed, nonverbal reasoning, executive functioning, working memory, and sustained attention. A computerized 7-point sedation item (0 [not sleepy] to 10 [very sleepy]) was completed prior to test battery. The Neurocognitive index score was derived from subtest scores per an algorithm. The index score and subtest scores assessed the subject's changes in cognition. Scores were rated as above average (score >109), average (90 to 109), below average (80 to 89), or well below average (70 to 79).

    Measured: Baseline, Week 6, ET

  13. Change From Baseline in Movement Disorder Scales: Simpson-Angus Rating Scale (SARS)

    SARS: 10-item clinician rated instrument to assess parkinsonian symptoms (7 items) and related extrapyramidal side effects (3 items): gait, arm dropping, shoulder shaking, elbow rigidity, leg pendulousness, glabellar tap, tremor, and salivation. Head dropping (modified SARS item 7) substituted for head rotation. Anchored 5-point scale: range 0 (absence of condition, normal) to 4 (most extreme form of condition). Total score is sum of individual item scores (range 0 to 40); higher score indicates more affected.

    Measured: Baseline, Week 1 through Week 6

  14. Change From Baseline in Movement Disorder Scales: Barnes Akathisia Rating Scale (BAS) Global Clinical Assessment Item

    BAS: clinician rated scale to assess akathisia to determine the degree of subjective restlessness and distress associated with restlessness. First 3 items (Objective, Subjective, and Distress related to restlessness) rated on a 4-point scale with range 0 (no symptoms) to 3 (increased severity of symptoms). Item 4 Global Clinical Assessment of Akathisia rated on a 6-point scale range 0 (no symptoms) to 5 (increased severity of symptoms); higher score indicates increased severity. All rating are anchored. Only the Global Clinical Assessment of Akathisia was to be analyzed.

    Measured: Baseline, Week 1 through Week 6

  15. Change From Baseline in Movement Disorder Scales: Abnormal Involuntary Movement Scale (AIMS) Movement Cluster Score

    AIMS: clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe) (total possible score 0 to 40; higher score indicates greater severity); items 11 to 14 are No or Yes response to dental status and sleep movements. Only the sum of the first 7 items to be analyzed (AIMS Movement Cluster score). Total score 0 to 28; higher score indicates greater severity.

    Measured: Baseline, Week 1 through Week 6

  16. Number of Subjects Per Response on the School Placement Questionnaire: School Situation

    School placement questionnaire: parent or legal guardian assessed questionnaire to determine whether the child is currently enrolled in school (or planned to be enrolled if on school holiday like summer break), whether attending regularly if enrolled, and how well the child is doing overall in school. Questions were modified from those used in the National Institute of Mental Health (NIMH) funded Treatment of Early Onset Schizophrenia Spectrum (TEOSS) study. Results determine whether subjects are currently attending school and qualitatively describe how well they are doing in school.

    Measured: Baseline, Week 2, Week 6, ET

  17. Number of Subjects Per Response on the School Placement Questionnaire: School Attendance

    School placement questionnaire: parent or legal guardian assessed questionnaire to determine whether the child is currently enrolled in school (or planned to be enrolled if on school holiday like summer break), whether attending regularly if enrolled, and how well the child is doing overall in school. Questions were modified from those used in the National Institute of Mental Health (NIMH) funded Treatment of Early Onset Schizophrenia Spectrum (TEOSS) study. Results determine whether subjects are currently attending school and qualitatively describe how well they are doing in school.

    Measured: Baseline, Week 2, Week 6, ET

  18. Number of Subjects Per Response on the School Placement Questionnaire: Overall School Performance

    School placement questionnaire: parent or legal guardian assessed questionnaire to determine whether the child is currently enrolled in school (or planned to be enrolled if on school holiday like summer break), whether attending regularly if enrolled, and how well the child is doing overall in school. Questions were modified from those used in the National Institute of Mental Health (NIMH) funded Treatment of Early Onset Schizophrenia Spectrum (TEOSS) study. Results determine whether subjects are currently attending school and qualitatively describe how well they are doing in school.

    Measured: Baseline, Week 2, Week 6, ET

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2005 (estimated)
  2. Study startApr 2006
  3. Primary completionMar 2009
  4. Study completionMar 2009

Why it stopped: Please see Detailed Description for termination reason.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
284 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00257192
Sponsor's protocol ID
A1281134
Status last verified
Mar 2021
First submitted
21 Nov 2005
Last updated
25 Mar 2021
Data monitoring committee
Yes

Publications

  • Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol. 2013 Oct;23(8):531-44. doi: 10.1089/cap.2012.0068. Epub 2013 Oct 10.

    PubMed 24111983

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Ziprasidone oral capsules in people with Schizophrenia, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 92 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 25 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 92 sites in United States, Russia, Ukraine, India, Malaysia and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Apr 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score at Week 6 (time frame: Baseline, Week 6). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00257192, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in